Archives
-
NVP-BGJ398 Phosphate: Evidence and Scope
2026-10-14
APExBIO describes NVP-BGJ398 phosphate, or BGJ-398 phosphate, as a selective pan-FGFR1–3 inhibitor that acts by suppressing FGFR autophosphorylation and downstream ERK1/2 signaling. The available evidence is limited to supplier-reported biochemical, cellular, xenograft, and development-status claims; no identity-matched primary research paper or detailed outcome statistics are available for independent verification.
-
SUMO Protease (Ulp): Identity and Evidence Scope
2026-10-14
APExBIO’s K1103 is described as a recombinant yeast Ulp1-derived cysteine protease intended for conceptual SUMO fusion-tag removal. The available evidence supports product identity and intended use, but not independent performance, comparative efficacy, or target-specific applicability.
-
Anti-DYKDDDDK Magnetic Beads: Evidence Scope
2026-10-13
APExBIO’s K4207 is documented as a magnetic affinity-bead product bearing anti-Flag M2 monoclonal antibodies for conceptual capture of DYKDDDDK (Flag)-tagged proteins. The supplied evidence supports product identity and intended applications, but no matched peer-reviewed study is available to independently verify performance, binding capacity, reusability, or applicability across sample types.
-
Tropisetron Hydrochloride: Evidence and Boundaries
2026-10-13
Tropisetron Hydrochloride is described as a 5-HT3 receptor antagonist with additional α7-nicotinic receptor activity. In a 2021 cell-based study, tropisetron inhibited OCT2- and MATE1-associated transport, supporting a mechanistic basis for studying renal drug-transporter interactions. These findings remain preclinical and do not establish clinical interaction risk or generalize to every cationic drug.
-
Cas13d Control and the TEV Protease Boundary
2026-10-12
Zhu et al. report stimulus-responsive RfxCas13d variants created through domain insertion at an allosteric site, enabling light- or rapamycin-analog-dependent RNA knockdown. The study supports engineered allostery as a route to temporal control, but it does not evaluate TEV Protease, recombinant protein tag removal, or whether purification-related modifications preserve Cas13d activity.
-
PP 1 and the Evidence Around Src-Kinase Signaling
2026-10-12
PP 1 is described by APExBIO as a Src family tyrosine kinase inhibitor, whereas the supplied atrial-fibrillation study implicates C-terminal Src kinase (CSK) in an off-target effect of ibrutinib. These findings provide useful mechanistic context but do not establish PP 1 as a model of ibrutinib-associated atrial fibrillation or as evidence for clinical effects.
-
Protease Inhibitor Cocktail EDTA-Free: Evidence Overview
2026-10-10
This overview examines the research context, conceptual applications, and evidence boundaries of an EDTA-free protease inhibitor cocktail. It distinguishes supplier-reported formulation claims from published findings and explains why the supplied poultry study does not independently validate protease-inhibition performance.
-
Sulforaphane, Oxidative Stress, and NLRP3 in Colitis
2026-10-09
A 2024 mouse study links sulforaphane-mediated reduction of oxidative stress with suppression of NLRP3 inflammasome signaling in experimental colitis. Its combined animal and macrophage evidence strengthens a mechanistic hypothesis for inflammatory bowel disease research, while remaining preclinical and model-dependent.
-
H 89 2HCl in PKA Signaling Research
2026-10-09
H 89 2HCl is widely used as a pharmacological probe of cAMP-dependent protein kinase activity, but supplier-reported selectivity does not eliminate cellular off-target concerns. This overview compares its biochemical and cellular evidence with a recent Neuroligin 1–D2-MSN study, which implicates PKC rather than PKA in repetitive behavior phenotypes.
-
Biotin-XX Tyramide: Evidence, Uses and Limits
2026-10-08
A source-grounded overview of Biotin-XX Tyramide Reagent, including its conceptual role in tyramide signal amplification and proximity labeling, findings from a 2024 serotonin study, evidence strength, nomenclature, and applicability limits.
-
Pronase E in Ferroptosis Research Context
2026-10-08
This overview separates supplier-described properties of Pronase E from findings in a 2026 study of gramine, triple-negative breast cancer, and ferroptosis. It explains how a broad protease mixture may fit conceptually within proteomic research while emphasizing that the published cancer study does not establish a role for Pronase E, clinical efficacy, or a validated therapeutic application.
-
7-AAD Cell Viability Assay Kit: Reading CAR-T Death
2026-10-07
The 7-AAD Cell Viability Assay Kit can clarify how membrane compromise is interpreted in CD38 CAR-T studies. This evidence-focused guide separates target-cell killing, late apoptosis, necrosis, and CAR-T fratricide while defining the assay’s limitations.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-10-07
A 2026 Advanced Science study uses single-cell RNA and B-cell receptor profiling to connect the nutrient-poor, hypoxic primary central nervous system lymphoma microenvironment with SLC2A5-mediated fructose metabolism. The reported functional data identify SLC2A5 as a potential metabolic vulnerability in lymphoma cells and tumor-supportive macrophages, while also linking the metabolic state of the microenvironment to T-cell dysfunction.
-
Phosphatase Inhibitor Cocktail and EZHIP Signaling
2026-10-06
Explore how a Phosphatase Inhibitor Cocktail can preserve phosphorylation-dependent evidence without confusing sample stabilization with proof of kinase regulation. This article connects the K1015 product concept with the 2026 EZHIP signaling study while defining evidence boundaries, assay interpretation, and translational limitations.
-
SAR131675 and VEGFR-3 in Liver Fibrosis Research
2026-10-06
SAR131675 is a selective VEGFR-3 inhibitor used as a preclinical mechanistic probe in lymphangiogenesis, angiogenesis, cancer, and liver-fibrosis research. A recent Phytomedicine study linked VEGFC–VEGFR-3 signaling to hepatocyte–macrophage interactions in diet-associated hepatic fibrosis, but the evidence remains preclinical and does not establish clinical efficacy or safety.